LP
HAE icon

LMR Partners’s Haemonetics HAE Stock Holding History

LMR Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26,365
Closed -$2.06M – 1483
2024
Q4 		$2.06M Buy
+26,365
New +$2.12M 0.02% 599
2020
Q4 		– Sell
-19,462
Closed -$1.7M – 541
2020
Q3 		$1.7M Sell
19,462
-3,434
-15% -$300K 0.03% 167
2020
Q2 		$2.05M Buy
+22,896
New +$2.31M 0.05% 255

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.82B AUM 7.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

LMR Partners's HAE Position: Q1 2025 in Review

LMR Partners sold out of Haemonetics (HAE) in Q1 2025, closing a stake of 26,365 shares — an estimated $2.06M sold.

LMR Partners first reported a position in HAE in Q2 2020 and held it in 3 quarters. The position peaked at $2.06M in Q4 2024. 314 funds tracked by Wall St. Rank hold HAE as of Q1 2025.

  • LMR Partners reported no remaining Haemonetics position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 26,365 Haemonetics shares in Q1 2025, an estimated $2.06M.
  • LMR Partners first reported a position in Haemonetics in Q2 2020 and held it in 3 quarters.
  • LMR Partners's Haemonetics position peaked at $2.06M in Q4 2024.
  • 314 funds tracked by Wall St. Rank held Haemonetics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.